Errors in Table 1, Table 4, and Supplement 2 - Summary - MDSpire

Errors in Table 1, Table 4, and Supplement 2

  • May 1, 2026

  • 0 min

Share

Objective:

To address specific inaccuracies found in the original clinical trial publication regarding buprenorphine use in pregnancy, including participant data and infant outcomes.

Key Findings:
  • Table 1 had incorrect quantities and proportions of participants with DSM-5 use disorders.
  • Table 4 incorrectly reported the number of infants with congenital anomalies in the extended-release buprenorphine cohort, which should be 4.
  • eTable 1 of Supplement 2 misreported the mean days on replacement medication for pregnancy (74.0 days) and postpartum (39.7 days).
Interpretation:

The corrections ensure accurate reporting of data related to buprenorphine use in pregnancy, which is crucial for understanding its effects on maternal and infant health.

Limitations:
  • The article does not specify the implications of these corrections on the study's overall findings, which could affect the interpretation of results.
Conclusion:

The article has been amended to reflect accurate data.

Original Source(s)

Errors in Table 1, Table 4, and Supplement 2

  • May 1, 2026

Related Content

Addressing the Health Needs of People Who Inject Drugs: A Descriptive Analysis of an Inpatient Integrated Care Team Within an Acute Hospital in Scotland

Leveraging Natural Language Processing to Identify Veterans Who Inject Drugs to Assess Preexposure Prophylaxis and Sexually Transmitted Infection Testing Services at the Veterans Health Administration

Fabricated Citations Are Reaching Medical Journals

A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.